Expression of transient receptor potential vanilloid-1 (TRPV1) in urothelial cancers of human bladder: Relation to clinicopathological and molecular parameters

Histopathology

Volumn 57, Issue 5, 2010, Pages 744-752

  Kalogris, Cristina ^a   Caprodossi, Sara ^a   Amantini, Consuelo ^a   Lambertucci, Federica ^b   Nabissi, Massimo ^a   Morelli, Maria Beatrice ^c   Farfariello, Valerio ^c   Filosa, Alessandra ^b   Emiliozzi, Maria Cristina ^b   Mammana, Gabriele ^d   Santoni, Giorgio ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b Pathology and Cytodiagnostic Unit   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Urology Operative Unit   (Italy)

Author keywords

Bladder; Kaplan Meier; Survival; Transient receptor potential vanilloid type 1 (TRPV1); Transitional cell carcinoma; Urothelium

Indexed keywords

MESSENGER RNA; VANILLOID RECEPTOR 1;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RISK ASSESSMENT; UROTHELIAL CANCER;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRPV CATION CHANNELS; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

FILOSEA;

EID: 78449304113     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03683.x     Document Type: Article

References (36)

1. Ferlay J, Bray F, Pisani P et al. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide: version 1.0 IARC cancer base no. 5. Lyon: IARC Press, Cours Albert Thomas, 2001.
2. Sternberg CN, Calabro F. Chemotherapy and management of bladder tumours. BJU Int. 2000; 85; 599-610.
3. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin. 2005; 55; 10-30.
4. Prout GR Jr. Bladder carcinoma and a TNM system of classification. J. Urol. 1977; 117; 583-590.
5. Scarpelli M, Montironi R, Tarquini LM et al. Karyometry detects subvisual differences in chromatin organization state between non-recurrent and recurrent papillary urothelial neoplasms of low malignant potential. J. Clin. Pathol. 2004; 57; 1201-1207.
6. Egawa S, Kuruma H. Search for biomarkers of aggressiveness in bladder cancer. Eur. Urol. 2006; 50; 20-22.
7. Yurakh AO, Ramos D, Calabuig-Farinas S et al. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of bladder. Eur. Urol. 2006; 50; 506-515.
8. Thalmann GN. Prognostic markers for bladder cancer - are we there yet? Eur. Urol. 2007; 51; 591-592.
9. Kunzelmann K. Ion channel and cancer. J. Membrane Biol. 2005; 205; 159-173.
10. Gkika D, Prevarskaya N. Molecular mechanisms of TRP regulation in tumor growth and metastasis. Biochim. Biophys. Acta 2009; 1793; 953-958.
11. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389; 816-824.
12. Amantini C, Mosca M, Lucciarini R et al. Distinct thymocyte subsets express the vanilloid receptor VR1 that mediates capsaicin-induced apoptotic cell death. Cell Death Differ. 2004; 11; 1342-1356.
13. Birder LA, Kanai AJ, De Groat WC et al. Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc. Natl Acad. Sci. USA 2001; 98; 13396-13401.
14. Avelino A, Cruz F. TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch. Pharmacol. 2006; 373; 287-299.
15. Lazzeri M, Vannucchi MG, Zardo C et al. Immunohistochemical evidence of vanilloid receptor in normal human urinary bladder. Eur. Urol. 2004; 46; 792-798.
16. Apostolidis A, Brady CM, Yiangou Y, Davis J, Fowler CJ, Anand P. Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravescical resinferatoxin. Urology 2005; 65; 400-405.
17. Birder LA. More than just a barrier: urothelium as a drug target for urinary bladder pain. Am. J. Physiol. Renal Physiol. 2005; 285; 489-495.
18. Birder LA, Nakamura Y, Kiss S et al. Altered urinary bladder function in mice lacking the vailloid receptor TRPV1. Nat. Neurosci. 2002; 5; 856-860.
19. Birder LA. TRPs in bladder diseases. Biochim. Biophys. Acta 2007; 772; 879-884.
20. Lazzeri M, Vannucchi MG, Spinelli M et al. Transient receptor vanilloid type 1 (TRPV1) expression changes from normal urothelial to transitional cell carcinoma of human bladder. Eur. Urol. 2005; 48; 691-698.
21. Sanchez MG, Sanchez AM, Collado B et al. Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue. Eur. J. Pharmacol. 2005; 515; 20-27.
22. Prevarskaya N, Zhang L, Barritt G. TRP channels in cancer. Biochim. Biophys. Acta 2007; 1772; 937-946.
23. Domotor A, Peidl Z, Vineze A et al. Immunohistochemical distribution of vanilloid receptor, calcitonin-gene related peptide and substance P in gastrointestinal mucosa of patients with different gastrointestinal disorders. Inflammopharmacology 2005; 13; 161-177.
24. Hartel M, Di Mola FF, Selvaggi F et al. Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. Gut 2006; 55; 519-528.
25. Amantini C, Mosca M, Nabissi M et al. Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J. Neurochem. 2007; 102; 977-990.
26. Amantini C, Ballarini P, Caprodossi S et al. Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. Carcinogenesis 2009; 30; 1320-1329.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T) method). Methods 2001; 25; 402-408.
28. 2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene 2003; 22; 7858-7861.
29. Czifra G, Varga A, Nyeste K et al. Increased expression of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J. Cancer Res. Clin. Oncol. 2009; 135; 507-514.
30. 2+/NFAT-dependent pathways. Oncogene 2007; 26; 7380-7385.
31. Monet M, Gkika D, Lehen'kyi V et al. Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim. Biophys. Acta 2009; 1793; 528-539.
32. Caprodossi S, Lucciarini R, Amantini C et al. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage. Eur. Urol. 2008; 54; 612-620.
33. Millan-Rodriguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J. Urol. 2000; 164; 680-684.
34. Sindhwani P, Hampton JA, Baig MM, Keck R, Selman SH. Curcumin prevents intravescical tumor implantation of the MBT-2 tumor cell line in C3H mice. J. Urol. 2001; 6; 1498-1501.
35. Furukawa J, Miyake H, Takenaka A, Fujisawa M. Clinical outcome of radical cystectomy for patients with pT4 bladder cancer. Int. J. Urol. 2008; 15; 58-61.
36. Miao X, Liu G, Xu X et al. High expression of vanilloid receptor-1 is associated with better prognosis of patients with hepatocellular carcinoma. Cancer Genet. Cytogenet. 2008; 186; 25-32.